AUSTIN, Texas, Sept. 10, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX), today announced that it will host Planet xMAP Europe 2012, its annual European multiplexing technology symposium, October 10-11, 2012 at the Grimaldi Forum in the Principality of Monaco. Luminex anticipates attendance of over 500 scientists and more than 40 scientific presentations to be addressed during the 10th anniversary event. The two-day program features scientific sessions, workshops, discussion groups, exhibitions and networking events with scientists and researchers from around the world who are performing groundbreaking work in clinical diagnostics and life science research using Luminex's technology platforms.
"We are excited to have scientists from around the world share their latest research and to see the continued growth in new applications for multiplexing technology," said Paul C. Ladestein, General Manager European Operations for Luminex. "The focus this year is on new developments in the areas of newborn screening, infectious disease, immunology-monitoring, human genetics, protein and nucleic acid research. Planet xMAP Europe is always an excellent opportunity for leading scientists to gather and exchange ideas on how xMAP multiplexing technology is revolutionizing their laboratories and research. Our 10th anniversary event highlights the contributions our technology is making in advancing research and healthcare around the globe."
Planet xMAP Europe 2012 will feature two days of presentations with keynote lectures from:
Day One of Planet xMAP Europe 2012, Wednesday, 10 October, will focus on Pathogen Detection, Gastrointestinal Infections, Respiratory Viral Infections, and Newborn ScreeningThe morning session will include the following presentations:
30 years experience in the fight against infectious diseases in Haiti
Dr. Jean William Pape, GHESKIO Centers,Weill Medical College of Cornell University, Haiti
Multiplex Diagnosis Reveals New Challenges for Malaria Elimination
Dr. Peter A. Zimmerman, Case Western University, Cleveland, Ohio
Rational multiplex serological screening system for common pathogens using suspension arrays
Dr. Jonas Blomberg, Clinical Microbiology, Academic Hospital, Uppsala, Sweden
Preliminary findings of a Health Economic Study of the Luminex xTAG® Gastrointestinal Pathogen Panel at Guy's & St. Thomas' NHS trust 2011-12
Dr. Eugene Halligan, Guy's & St. Thomas' Hospital, London, UK
Newborn Screening: Current Situation and Future Applications
Dr. David C. Kasper, Medical University of Vienna, Vienna, Austria
The afternoon session will feature three separate tracks focused on Human Genetics, Immunology-Monitoring, and Pathogen Detection.
Day Two of Planet xMAP Europe 2012, Thursday, 11 October, will focus on Neural Stem Cells, Tumor Microenvironment, the Immune-Proteome, and Cellular SystemsThe morning session will include the following presentations:
Chronic inflammatory and immunosuppressive conditions in tumor microenvironment and their neutralization
Dr. Viktor Umansky, German Cancer Research Center, Heidelberg and University Hospital Mannheim, Germany
Systematic high-throughput / high content analysis of the immune-proteome using Luminex-based multiplex arrays
Dr. Peter Schulz-Knappe, Protagen AG, Dortmund, Germany
The afternoon session will feature two separate tracks focused on Genomic and Protein Research.
For detailed information regarding the Planet xMAP Europe 2012 symposium and agenda, or to register online, please visit http://www.planetxmap.com .
About Luminex CorporationLuminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com .Contacts Corporate:
Media: Harriss T. Currie
Mimi TorringtonChief Financial Officer and Vice President, Finance
Director, Marketing CommunicationsLuminex Corporation
Luminex Corporation email@example.com
Aaron DeLucia:Matthew Scalo
Porter NovelliSr. Director, Investor Relations
Aaron.DeLucia@porternovelli.com Luminex Corporation
|SOURCE Luminex Corporation|
Copyright©2012 PR Newswire.
All rights reserved